GW23-e0619

**HEPATOCYTE GROWTH FACTOR GENETICALLY
MODIFIED BONE MARROW-DERIVED MESENCHYMAL
STEM CELLS TRANSPLANTATION PROMOTES
ANGIOGENESIS IN A RAT MODEL OF HINDLIMB
ISCHAEMIA**

doi:10.1136/heartjnl-2012-302920a.213

Guanhua Su, Yufei Sun, Yongxin Lu, Xinxin Shuai, Yuhua Liao, Qiyun Liu, ping Luo, Yongxin Lu. *Department of Cardiology, Union Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430022, China*

Objectives Angiogenic gene therapy and cell-based therapy for peripheral arterial disease (PAD) have been studied intensively

currently. This study aimed to investigate a new strategy whether combining mesenchymal stem cells (MSCs) transplantation with ex vivo human hepatocyte growth factor (HGF) gene transfer was more therapeutically efficient than the MSCs therapy alone in a rat model of hindlimb ischaemia.

Methods One-week after establishing hindlimb ischaemia models, Sprague-Dawley rats were randomised to receive HGF gene-modified MSCs transplantation (HGF-MSC group), untreated MSCs transplantation (MSC group), or PBS injection (PBS group), respectively.

Results Three-weeks after injection, angiogenesis was significantly induced by both MSCs and HGF-MSCs transplantation, and capillary density was the highest in the HGF-MSC group. The number of transplanted cell-derived endothelial cells was greater in HGF-MSC group than in MSC group after 1 week treatment. The expression of angiogenic cytokines such as HGF and VEGF in local ischaemic muscles was more abundant in HGF-MSC group than in the other two groups. In vitro, the conditioned media obtained from HGF-MSCs cultures presented proliferative and promigratory effects on endothelial cells.

Conclusions HGF gene-modified MSCs transplantation therapy may induce more potent angiogenesis than the MSCs therapy alone. Engraftment of MSCs combined with angiogenic gene delivery maybe a promising therapeutic strategy for the treatment of severe PAD.